Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

2018 ◽  
Vol 21 (2) ◽  
pp. 285-292 ◽  
Author(s):  
Masanori Shimizu ◽  
Kunihiro Suzuki ◽  
Kanako Kato ◽  
Teruo Jojima ◽  
Toshie Iijima ◽  
...  
2014 ◽  
Vol 31 (9) ◽  
pp. 1039-1046 ◽  
Author(s):  
S. J. Jenks ◽  
B. R. Conway ◽  
T. J. Hor ◽  
R. M. Williamson ◽  
S. McLachlan ◽  
...  

2021 ◽  
Vol 11 (3) ◽  
pp. 238
Author(s):  
Hui-Ju Tsai ◽  
Yi-Chun Tsai ◽  
Wei-Wen Hung ◽  
Wei-Chun Hung ◽  
Chen-Chia Chang ◽  
...  

Introduction: Non-alcoholic fatty liver disease (NAFLD) remains an important health issue worldwide. The increasing prevalence of NAFLD is linked to type 2 diabetes (T2D). The gut microbiota is associated with the development of NAFLD and T2D. However, the relationship between gut microbiota and NAFLD severity has remained unclear in T2D patients. The aim of this study was to evaluate the relationship of gut microbiota with the severity of NAFLD in T2D patients. Methods: This cross-sectional study used transient elastography (FibroScan) to evaluate the severity of hepatic steatosis. We utilized qPCR to measure the abundance of Bacteroidetes, Firmicutes, Faecalibacterium prausnitzii, Clostridium leptum group, Bacteroides, Bifidobacterium, Akkermansia muciniphila, and Escherichia coli. Results: Of 163 T2D patients, 83 with moderate to severe NAFLD had higher abundance of bacteria of the phylum Firmicutes with respect to 80 patients without NAFLD or with mild NAFLD. High abundance of the phylum Firmicutes increased the severity of NAFLD in T2D patients. A positive correlation between NAFLD severity and the phylum Firmicutes was found in T2D male patients with body mass index ≥24 kg/m2 and glycated hemoglobin <7.5%. Conclusion: Enrichment of the fecal microbiota with the phylum Firmicutes is significantly and positively associated with NAFLD severity in T2D patients. The gut microbiota is a potential predictor of NAFLD severity in T2D patients.


2014 ◽  
Vol 02 (02) ◽  
pp. 087-091 ◽  
Author(s):  
Kuhu Roy ◽  
Uma Iyer

Abstract Introduction: Non alcoholic fatty liver disease is emerging as a public health problem among type 2 diabetes mellitus patients. It has an impact on quality of life, which is meagrely explored. Aim: To assess quality of life of type 2 diabetes patients with newly diagnosed non alcoholic fatty liver disease. Materials and Methods: Confirmed cases of newly diagnosed non alcoholic fatty liver disease with type 2 diabetes mellitus (n = 55) were enrolled. Clinical, anthropometric and medical profiles were assessed. Quality of life was assessed with the help of quality of life instrument for Indian diabetes patients. Results: Weight (P = 0.005) and body mass index (P 0.008) in grade 3 hepatic steatosis were higher than grade 2 steatosis. Physical health deteriorated from grade 1 to grade 3 hepatic steatosis. The mean likert scores decreased significantly (P 0.000) from grade 2 to grade 3 and between grade 1 and grade 3 (P 0.0014) hepatic steatosis in the physical endurance domain. Perceptions regarding general health and treatment satisfaction revealed existing loopholes in the health system and one′s general attitude towards health. The dietary domain was marked with gross dissatisfaction amongst most with hepatic steatosis with a significant reduction in mean likert scale score between grade 1 and grade 2 (P 0.012) of hepatic steatosis. Conclusions: Modifiable domains of quality of life should be addressed as a core component of standard care in newly diagnosed non alcoholic fatty liver disease with type 2 diabetes mellitus to avert future cardiac and hepatic events.


2020 ◽  
Author(s):  
Minyoung Lee ◽  
Kwang Joon Kim ◽  
Tae Ha Chung ◽  
Jaehyun Bae ◽  
Yong-ho Lee ◽  
...  

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes and is associated with cardiovascular risk. We investigated whether the degree of NAFLD was associated with myocardial dysfunction related to impaired myocardial glucose uptake in patients with type 2 diabetes. Methods In total, 131 patients with type 2 diabetes from a tertiary care hospital were included. Myocardial glucose uptake was assessed using [18F]-fluorodeoxyglucose-positron emission tomography. Hepatic steatosis and fibrosis were determined using transient liver elastography. Echocardiography was performed to evaluate cardiac structure and function. Results Patients with NAFLD revealed cardiac diastolic dysfunction with higher left ventricular filling pressure (E/e’ ratio) and left atrial volume index (LAVI) than patients without NAFLD (all p < 0.05). Hepatic steatosis correlated with E/e’ ratio and LAVI, and hepatic fibrosis also correlated with E/e’ ratio (all p < 0.05). In linear regression analyses, a higher degree of hepatic steatosis (r2 = 0.409; p = 0.041) and a higher degree of fibrosis (r2 = 0.423; p = 0.009) were independent determinants for a higher E/e’ ratio even after adjusting for confounding factors. Decreased myocardial glucose uptake was associated with a higher degree of steatosis (p for trend = 0.084) and fibrosis (p for trend = 0.012). In addition, decreased myocardial glucose uptake was an independent determinant factor for a higher E/e’ ratio (r2 = 0.409; p = 0.04). Conclusions Hepatic steatosis and fibrosis are significantly associated with diastolic heart dysfunction in patients with type 2 diabetes coupled with impaired myocardial glucose uptake.


Sign in / Sign up

Export Citation Format

Share Document